RxDoctor Payments Data

Lisa Ben-Aderet

Family · Bayside, NYNPI 1861951113

Payments from drug & device makers

$5,028in general payments, 2019–2025

Across 236 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$368
  • Novo Nordisk$338
  • Biohaven Pharmaceuticals, Inc.$217
  • Biohaven Pharmaceutical Holding Company Ltd.$166
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,028100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,028 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$49,129
BiktarvyBictegrav/Emtricit/Tenofov Ala11$43,316
EliquisApixaban33$23,801
JanuviaSitagliptin Phosphate31$23,199
JardianceEmpagliflozin18$18,856
UbrelvyUbrogepant11$17,529
TradjentaLinagliptin17$15,288
VascepaIcosapent Ethyl11$6,260
SynthroidLevothyroxine Sodium27$2,680
Sucralfate14$1,860
Albuterol Sulfate HfaAlbuterol Sulfate43$1,686
Rosuvastatin Calcium119$1,284
Omega-3 Acid Ethyl Esters13$1,222
Levocetirizine Dihydrochloride90$1,119
Levothyroxine Sodium79$1,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$338$49,12934 claims
PfizerEliquis$70$23,80133 claims
MerckJanuvia$89$23,19931 claims
AbbVieUbrelvy, Synthroid$1,854$20,20938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Bayside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →